Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 149-156 , September 2010

Managing Coronary Artery Disease in the Cancer Patient

  • Ronald J. Krone

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Ronald J. Krone, MD, Professor, Department of Medicine, Division of Cardiology, Washington University School of Medicine, 660 S Euclid, Box 8086, St. Louis, MO 63130.

References 

  1. Heron M, Hoyert DL, Murphy S, et al. Deaths: final data for 2006. Natl Vital Stat Rep. 2009;57
  2. Ross R. Atherosclerosis—An inflammatory disease. N Engl J Med. 1999;340:115–126
  3. Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138
  4. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  5. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque: Part I: Evolving concepts. J Am Coll Cardiol. 2005;46:937–954
  6. Halle M, Gabrielsen A, Paulsson-Berne G, et al. Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. J Am Coll Cardiol. 2010;55:1227–1236
  7. Gayed IW, Liu HH, Wei X, et al. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009;4:179–184
  8. Gallucci G, Capobianco AM, Coccaro M, et al. Myocardial perfusion defects after radiation therapy and anthracycline chemotherapy for left breast cancer: a possible marker of microvascular damage. Three cases and review of the literature. Tumori. 2008;94:129–133
  9. Armenian SH, Sun CL, Mills G, et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:1138–1144
  10. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003;45:55–75
  11. Adabag AS, Dykosk R, Ward H, et al. Critical stenosis of aortic and mitral valves after mediastinal irradiation. Catheter Cardiovasc Interv. 2004;63:247–250
  12. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159–168
  13. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516
  14. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–2515
  15. Rihal CS, Raco DL, Gersh BJ, et al. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the Evidence and Methodological Considerations. Circulation. 2003;108:2439–2445
  16. Chandra S, Lenihan DJ, Wei W, et al. Myocardial perfusion imaging and cardiovascular outcomes in a cancer population. Tex Heart Inst J. 2009;36:205–213
  17. Fraker TD, Fihn SD Writing on behalf of the Chronic Stable Angina Writing Committee. 2007 Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients With Chronic Stable Angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 Guidelines for the Management of Patients With Chronic Stable Angina. J Am Coll Cardiol. 2007;50:2264–2274
  18. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148–304
  19. Kushner FG, Hand M, Smith SC, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205–2241
  20. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation. 1998;98:1597–1603
  21. King SB, Smith SC, Hirshfeld JW, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:172–209
  22. Krone RJ, Rao SV, Dai D, et al. Acceptance, panic and partial recovery-The pattern of usage of drug eluting stents after introduction in the United States- (A report from the American College of Cardiology / National Cardiovascular Data Registry (ACC/NCDR®)). JACC Cardiovasc Interv. 2010;
  23. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202
  24. Takano M, Ohba T, Inami S, et al. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J. 2006;27:2189–2195[see comment]
  25. Grines CL, Bonow RO, Casey DE, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, With Representation From the American College of Physicians. Circulation. 2007;115:813–818
  26. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J. 2009;30:2769–2812
  27. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007;116:e418–e499
  28. Moscucci M, Eagle KA. Coronary revascularization before noncardiac surgery. N Engl J Med. 2004;351:2861–2863
  29. Poldermans D, Schouten O, Vidakovic R, et al. A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V pilot study. J Am Coll Cardiol. 2007;49:1763–1769
  30. Poldermans D. Statins and noncardiac surgery: current evidence and practical considerations. Cleve Clin J Med. 2009;76(Suppl 4):S79–S83
  31. Boersma E, Kertai MD, Schouten O, et al. Perioperative cardiovascular mortality in noncardiac surgery: validation of the Lee cardiac risk index. Am J Med. 2005;118:1134–1141
  32. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008;371:1839–1847
  33. London MJ. New practice guidelines for perioperative beta blockade from the United States and Europe: incremental progress or a necessary evil?. Can J Anaesth. 2010;57:301–312
  34. Schouten O, Boersma E, Hoeks SE, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. N Engl J Med. 2009;361:980–989
  35. Briguori C, Visconti G, Focaccio A, et al. Novel Approaches For Preventing Or Limiting Events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol. 2009;54:2157–2163
  36. Cardiac Society of Australia and New Zealand -CSANZ. Guidelines for the management of antiplatelet therapy in patients with coronary stents undergoing non-cardiac surgery. Heart, Lung and Circulation. 2010;19:2–10
  37. Brilakis ES, Orford JL, Fasseas P, et al. Outcome of patients undergoing balloon angioplasty in the two months prior to noncardiac surgery. Am J Cardiol. 2005;96:512–514
  38. Kaluza GL, Joseph J, Lee JR, et al. Catastrophic outcomes of noncardiac surgery soon after coronary stenting. J Am Coll Cardiol. 2000;35:1288–1294
  39. Wilson SH, Fasseas P, Orford JL, et al. Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol. 2003;42:234–240
  40. Broad L, Lee T, Conroy M, et al. Successful management of patients with a drug-eluting coronary stent presenting for elective, non-cardiac surgery. Br J Anaesth. 2007;98:19–22
  41. Brilakis ES, Banerjee S, Berger PB. Perioperative Management of Patients With Coronary Stents. J Am Coll Cardiol. 2007;49:2145–2150
  42. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. N Engl J Med. 2004;351:2795–2804
  43. Sarkiss MG, Yusuf SW, Warneke CL, et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer. 2007;109:621–627
  44. Tornio A, Pasanen MK, Laitila J, et al. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol. 2005;97:104–108
  45. Khaidakov M, Wang W, Khan JA, et al. Statins and angiogenesis: is it about connections?. Biochem Biophys Res Commun. 2009;387:543–547
  46. Elewa HF, El-Remessy AB, Somanath PR, et al. Diverse effects of statins on angiogenesis: new therapeutic avenues. Pharmacotherapy. 2010;30:169–176
  47. Mehta NG, Mehta M. Overcoming multidrug resistance in cancer: statins offer a logical candidate. Med Hypotheses. 2010;74:237–239
  48. Gonyeau MJ, Yuen DW. A clinical review of statins and cancer: helpful or harmful?. Pharmacotherapy. 2010;30:177–194
  49. Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med. 2010;123:60–65
  50. Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. AM J Med. 2009;122:407–408
  51. Ellis SG, Bhatt D, Kapadia S, et al. Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. Catheter Cardiovasc Interv. 2006;67:541–545
  52. Rao SV, Ou FS, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2008;1:379–386
  53. Bertrand OF, Larose E, Rodes-Cabau J, et al. Incidence, predictors, and clinical impact of bleeding after transradial coronary stenting and maximal antiplatelet therapy. Am Heart J. 2009;157:164–169
  54. Helft G, Dambrin G, Zaman A, et al. Percutaneous coronary intervention in anticoagulated patients via radial artery access. Catheter Cardiovasc Interv. 2009;73:44–47
  55. Heir JS, Gottumukkala V, Singh M, et al. Coronary stents and noncardiac surgery: current clinical challenges and conundrums. Prev Cardiol. 2010;13:8–13
  56. Khakoo AY, Yeh ET. Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. Nat Clin Pract Oncol. 2008;5:655–667
  57. Gross CM, Posch MG, Geier C, et al. Subacute coronary stent thrombosis in cancer patients. J Am Coll Cardiol. 2008;51:1232–1233
  58. Smith SC, Winters KJ, Lasala JM. Stent thrombosis in a patient receiving chemotherapy. Cathet Cardiovasc Diagn. 1997;40:383–386
  59. Ko DT, Chiu M, Guo H, et al. Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. J Am Coll Cardiol. 2009;53:1773–1782
  60. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  61. Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003;72:43–52
  62. Elice F, Jacoub J, Rickles FR, et al. Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol. 2008;83:862–870
  63. Brown ML, Schaff HV, Sundt TM. Conduit choice for coronary artery bypass grafting after mediastinal radiation. J Thorac Cardiovasc Surg. 2008;136:1167–1171
  64. Gansera B, Schmidtler F, Angelis I, et al. Quality of internal thoracic artery grafts after mediastinal irradiation. Ann Thorac Surg. 2007;84:1479–1484
  65. Noble S, Pasi J. Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 2010;102(Suppl 1):S2–S9
  66. Karp I, Behlouli H, Lelorier J, et al. Statins and cancer risk. Am J Med. 2008;121:302–309
  67. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673–681[erratum appears in Lancet 1998 Oct 31;352(9138):1478]
  68. Sedlis SP, Boden WE, Weintraub WS, et al. Re: one year perspective on COURAGE. Catheter Cardiovasc Interv. 2009;73:428

 Statement of Conflict of Interest: see page 154.

PII: S0033-0620(10)00109-X

doi: 10.1016/j.pcad.2010.06.004

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 149-156 , September 2010

Article Tools